0.3651

4.40% 0.0154

Relmada Therapeutics Inc (RLMD)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$0.3497

Aprire:

$0.3498

Volume 24 ore:

1.20M

Relative Volume:

0.58

Capitalizzazione di mercato:

$21.41M

Reddito:

Utile/perdita netta:

$-98.79M

Rapporto P/E:

-0.1117

EPS:

-3.27

Flusso di cassa netto:

$-51.66M

1 W Prestazione:

-43.40%

1M Prestazione:

+20.46%

6M Prestazione:

-89.54%

1 anno Prestazione:

-90.19%

Intervallo 1D:

$0.3315

$0.3841

Intervallo di 1 settimana:

$0.2675

$0.7409

Portata 52W:

$0.2404

$4.47

Relmada Therapeutics Inc Stock (RLMD) Company Profile

Nome

Relmada Therapeutics Inc

Settore

Healthcare (1151)

Industria

Biotechnology (677)

Telefono

646 876 3459

Indirizzo

2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY

Dipendente

Cinguettio

@relmada

Prossima data di guadagno

2025-03-25

Ultimi documenti SEC

RLMD's Discussions on Twitter

Confronta RLMD con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RLMD	3.03	0	0	0	0	0.00
GOODO Gladstone Commercial Corporation	20.23	372.90M	0	0	0	0.00
PSNYW Polestar Automotive Holding Uk	0.1601	355.59M	2.07B	-1.42B	-1.37B	-0.6765
MOBBW Mobilicom Limited Warrants	0.2199	318.40M	0	0	0	0.00
JUNE Dhandho Junoon Etf	11.50	211.65M	0	0	0	0.00
SHMD Schmid Group N V	4.00	156.75M	0	0	0	0.00

Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-05	Downgrade	Mizuho	Outperform → Neutral
2024-09-17	Aggiornamento	Jefferies	Hold → Buy
2024-06-05	Downgrade	Goldman	Neutral → Sell
2022-10-14	Downgrade	Goldman	Buy → Neutral
2022-10-14	Downgrade	Guggenheim	Buy → Neutral
2022-10-14	Downgrade	Truist	Buy → Hold
2022-10-13	Downgrade	Oppenheimer	Outperform → Perform
2021-11-18	Iniziato	Mizuho	Buy
2021-05-20	Ripresa	Goldman	Buy
2020-10-28	Downgrade	Goldman	Buy → Neutral
2020-07-14	Iniziato	Oppenheimer	Outperform
2020-05-04	Iniziato	SunTrust	Buy
2020-04-21	Iniziato	Goldman	Buy
2020-01-27	Iniziato	Jefferies	Buy
2020-01-10	Iniziato	SVB Leerink	Outperform
2019-12-16	Iniziato	Guggenheim	Buy

Mostra tutto

Relmada Therapeutics Inc Borsa (RLMD) Ultime notizie

May 02, 2025

Relmada Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView

May 02, 2025

May 01, 2025

Chief Executive Officer TRAVERSA SERGIO acquire 51,407 shares of Relmada Therapeutics Inc [RLMD] - knoxdaily.com

May 01, 2025

Apr 30, 2025

It makes sense and dollars to buy Relmada Therapeutics Inc (RLMD) stock - Sete News

Apr 30, 2025

Apr 29, 2025

AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News

Apr 29, 2025

Market Insights: Relmada Therapeutics Inc (RLMD)’s Notable Drop of -44.64, Closing at 0.36 - DWinneX

Apr 29, 2025

Relmada Therapeutics (RLMD) Reports Promising Phase 2 Results fo - GuruFocus

Apr 29, 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Da - GuruFocus

Apr 29, 2025

Apr 28, 2025

Taking a Closer Look At Relmada Therapeutics Inc (RLMD) Following Its Recent Trade - knoxdaily.com

Apr 28, 2025

Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment - marketscreener.com

Apr 28, 2025

Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - marketscreener.com

Apr 28, 2025

Relmada reports strong Phase 2 results for bladder cancer drug By Investing.com - Investing.com Canada

Apr 28, 2025

Relmada reports strong Phase 2 results for bladder cancer drug - Investing.com

Apr 28, 2025

SEC Form 424B5 filed by Relmada Therapeutics Inc. - Quantisnow

Apr 28, 2025

Relmada Therapeutics (RLMD) Presents Positive Initial Phase 2 NDV-01 Data - StreetInsider

Apr 28, 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - Quantisnow

Apr 28, 2025

Breakthrough: Relmada's New Bladder Cancer Drug Achieves 90% Disease-Free Rate in Phase 2 Trial - Stock Titan

Apr 28, 2025

Relmada Therapeutics Inc: Rising -85.57% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com

Apr 28, 2025

Relmada Therapeutics (RLMD) to Discuss NDV-01 Phase 2 Study Resu - GuruFocus

Apr 28, 2025

Apr 27, 2025

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - GuruFocus

Apr 27, 2025

Relmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder Cancer - Nasdaq

Apr 27, 2025

Groundbreaking Bladder Cancer Treatment Data: Relmada's NDV-01 Takes Center Stage at AUA2025 - Stock Titan

Apr 27, 2025

Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025

Stock Performance Spotlight: Relmada Therapeutics Inc (RLMD) Ends the Day at 0.74, Up by 6.86 - DWinneX

Apr 25, 2025

Apr 24, 2025

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data - The Manila Times

Apr 24, 2025

Bridgeline Digital Secures Elite SOC 2 Type II Certification: What This Means for Enterprise Security - Stock Titan

Apr 24, 2025

Take off with Relmada Therapeutics Inc (RLMD): Get ready for trading - Sete News

Apr 24, 2025

Apr 23, 2025

RLMD’s price-to-free cash flow ratio: What it means for investors - uspostnews.com

Apr 23, 2025